Many tests are used to assess proteins and other substances in the blood of multiple myeloma patients. These tests measure levels of blood calcium, total protein, serum beta-2 microglobulin, LDH, C-reactive protein, and blood glucose. They are used to monitor the disease and its potential complications.
These tests are part of a basic medical exam and are useful in diagnosing and monitoring myeloma.
Calcium
REFERENCE RANGE
9–10.5 mg/dL
This test is used to assess the “C” in the CRAB criteria – elevated Calcium in the blood. Calcium is stored in the bones and is released as part of normal bone remodeling (the body constantly breaks down and rebuilds bone). Myeloma grows in the bone marrow, where it changes the environment inside the marrow. At the same time, it causes a cascade of cellular events that can result in increased bone breakdown. Increased bone breakdown results in both an increased level of calcium in the blood and an increased risk of fractures. A high blood calcium level can also damage the kidneys. (see Tests to Assess Kidney Function).
Total Protein Test Measure
REFERENCE RANGE
6–8 g/dL
Total protein measures the total amount of blood protein, including both albumin (the most plentiful protein in the blood) and globulin. If M-protein is present in the blood, it will increase the amount of blood globulin. As a result, the amount of total blood protein will rise.
At diagnosis, an elevated total protein should prompt a doctor to order additional, more specific tests to see if the source of elevated globulin protein might be from myeloma. If you have been diagnosed and treated for active myeloma, your doctor will use more specific tests to assess the amount of M-protein in your blood and/or urine.
Beta-2 Microglobulin (β2-microglobulin, β2 M, β2M)
REFERENCE RANGE
0.70–1.80 mg/L
The serum β2M level indicates the amount and activity of the underlying myeloma. It is one of two blood proteins (the other is serum albumin) included in the revised International Staging System (R-ISS) to help understand the potential for the aggressiveness of newly diagnosed myeloma.
In addition to its function in staging myeloma during the initial work-up, β2M can be used to evaluate disease activity and to monitor response to treatment.
- A serum β2M of < 3.5 mg/L is considered stage I;
- between 3.5 mg/L and 5.5 mg/L is stage II; and
- ≥ 5.5 mg/L is stage III.
Lactate Dehydrogenase (LDH)
LDH REFERENCE RANGE
105–333 IU/L (international units per liter)
High LDH can be a sign of aggressive disease and is therefore included in the R-ISS to help determine prognosis. LDH is an enzyme found in almost all body tissues. It plays an important role in cellular respiration, the process by which glucose (a sugar) is converted into usable energy for cells. Although LDH is abundant in tissue cells, blood levels of the enzyme are normally low. However, when tissues are damaged by injury or disease, they release more LDH into the bloodstream. LDH rises when myeloma is actively growing.
C-reactive protein
REFERENCE RANGE
≤ 8.0 mg/L (in healthy individuals, < 8 mg/L)
CRP is an indicator of inflammation, and its measurement is used routinely in assessing heart disease and autoimmune diseases. CRP is produced by the liver and released into the bloodstream within a few hours after tissue injury, the start of an infection, or another cause of inflammation. Increased levels of CRP indicate active myeloma.
Blood Glucose or Blood Sugar Test
REFERENCE RANGE
70–100 mg/dL (fasting blood glucose level)
The level of glucose, a major source of energy for most cells, should be established before you start treatment. Also, it should be monitored carefully if you are taking dexamethasone or another glucocorticosteroid. These steroids, which are common components of myeloma treatment regimens, can cause the level of blood glucose (sugar) to rise. If not controlled, elevated blood sugar can result in diabetes.
Electrolytes
Electrolytes are substances that conduct electricity in the body. Examples of electrolytes include sodium, potassium, chloride, and bicarbonate. Electrolytes do the following:
- regulate nerve function
- regulate muscle function
- hydrate the body
- balance blood acidity and pressure
- rebuild damaged tissue
Your healthcare professional will evaluate your electrolyte levels to see if they are off. Electrolyte imbalances may cause kidney disease.
What's Next?
Certain tests measure the monoclonal protein that myeloma cells secrete into the blood and/or urine. Learn more about how these tests assess the amount and activity of myeloma.
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologists, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape.
Additionally, the content on this page is medically reviewed by myeloma physicians and healthcare professionals.
Last Medical Content Review:
March 11, 2025